Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flexible home or community delivery of natalizumab for relapsing-remitting multiple sclerosis
ACTRN12616000617460Phase 3Active, not recruiting
- Sponsor
- Dr Janakan Ravindran
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of natalizumab in multiple sclerosis (MS) (2 arms), sponsored by Dr Janakan Ravindran. Primary endpoint: Adverse events. Started Oct 2016; status: active, not recruiting.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ACTRN12616000617460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000617460.